fda warning bpc-157 unapproved peptide safety risk panel narrowly backs drug touted by Joe Rogan and other influencers Exciting news for peptides coming

The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)

Most patients notice improvement within 2-4 weeks

this equates to roughly 3.4 million people

This means less degradation, less first-pass metabolism, and a far more direct route to the bloodstream

Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ